ArticleScientific reports2026
A computational framework for optimizing radioiodine therapy protocols in metastatic thyroid cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer incidence is increasing, and radioactive iodine (RAI) therapy remains essential for the management of metastatic disease. However, marked inter-patient variability makes protocol selection challenging, particularly when balancing therapeutic efficacy against radioiodine induced toxicity. In this context, digital decision support tools can help explore alternative treatment strategies and support longitudinal monitoring. This study investigates the influence of key RAI protocol parameters (the number of treatment sessions (n), the interval between sessions ([Formula: see text]), and the administered activity per session (A)) on therapeutic response using a validated mechanistic compartmental model. A sensitivity analysis is performed to quantify how these parameters affect serum thyroglobulin ([Formula: see text]) kinetics, with particular emphasis on tumor cell doubling time ([Formula: see text]) under RAI exposure as a discriminating factor between responder and non-responder profiles. Based on this framework, a standalone freeware simulator (RAIR-Sim, RAItherapy Response Simulator) is developed to simulate protocol dependent [Formula: see text] trajectories from patient specific inputs and to support exploratory protocol planning. Future developments will focus on improving patient specific parameter estimation (including supervised learning strategies to update parameters at each session and account for their time variation) to further enhance individualized simulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.